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Abstract 
Objectives: The recent availability of potent oral iron chelators is renewing an interest in the 
assessment of the possible impact of HFE genetics in MDS.  
Methods: 36 newly diagnosed patients with MDS were studied for parameters of iron metabolism in 
addition to C282Y and H63D mutations of the HFE gene.  
Results: Mutations were present in 11 out of 36 patients (31%), which was not different from our 
general population and were equally distributed among MDS subtypes. Mutated patients had higher 
ferritin levels (p=0.039) and lower TIBC (p=0.018). Ferritin was found to be higher for the 
untransfused mutated patients (p=0.017), but not for transfusion-dependent patients in whom ferritin 
levels correlated significantly with the number of blood units received (p=0.04). There was no 
difference in the number of blood units received between the mutated and wild type patients. A new 
observation made was that the mutated patients had a lower overall survival (OS) in addition to a 
poorer leukemia free survival (LFS) (p=0.004 and p=0.003, respectively).  
Discussion: The HFE gene mutations are not more frequent in MDS patients. Iron overload in 
mutated patients was higher but there was no correlation found using supportive therapy for anaemia. 
The effect of mutations on survival could be mediated by changes in iron metabolism. 
Conclusion: The HFE gentopye may predict MDS prognosis and there is a need for further studies. It 
remains a challenging question if HFE mutated MDS patients should be considered for potent iron 
chelation therapy. 
Keywords 
Myelodysplastic syndrome; HFE; C282Y; H63D; Iron metabolism; Overall Survival 
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Introduction 
Myelodysplastic syndrome (MDS) is a heterogeneous group of clonal hematopoietic stem cell 
malignancies characterized by ineffective hematopoiesis, progressive cytopenias and high risk of 
transformation to acute leukemia. These patients are at risk of developing an iron-replete state and 
hemochromatosis due to frequent transfusion dependency and characteristics of the disease itself.
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Transfusion dependency has been recognized as an independent prognostic factor for the survival of 
patients with MDS
2
 and iron chelation therapy leads to the improvement of survival in these patients.
3-
5
  
Increased frequency of two hemochromatosis (HFE) gene mutations, C282Y and H63D, among MDS 
patients was reported by Varkony et al.
6
 This finding was confirmed only for a subset of MDS patients 
with RARS
7
 and could not be confirmed by other author groups for MDS patients in general.
7-9
 
Differences were attributed to a different geographic distribution of the HFE gene mutations among 
populations.   
No significant differences in serum ferritin concentration between mutated and wild type MDS 
patients were reported, in due to a small number of patients. It was shown however, that iron overload 
could develop with a lower number of transfusion units in mutated MDS patients.
6
 These findings are 
consistent with five large population studies whereby heterozygosity for HFE mutations was 
associated with subtle changes in iron metabolism (higher transferrin saturation) but not with higher 
serum ferritin concentrations.
10-14
   
In this study, we present the functional impact of HFE gene mutations on iron metabolism and 
survival of MDS patients. 
Patients 
We studied a group of 36 newly diagnosed patients with MDS, diagnosed in period from 2008 to 
2014. Of this group, 53% of the patients were male, median age at diagnosis was 74 years of age (53-
89). Among our patients 13 (36%) were diagnosed with refractory anemia (RA), 12 (33%) with 
refractory anemia with ring sideroblasts (RARS), seven (19%) with refractory anemia with excess of 
blasts (RAEB), two with RAEB1 and five with RAEB2, three (8%) with unclassified MDS and one 
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with 5q- syndrome. Patients with acute leukemia and signs of myelodysplasia at time of diagnosis 
were not included in this study.  
The study protocol was approved by the University Hospital Dubrava’s review board. All subjects 
involved in this study provided written informed consent. 
Methods 
Parameters of iron metabolism (Fe, TIBC, UIBC and ferritin) were measured repeatedly during the 
follow-up period and the most recent follow up data was used.  
Genomic DNA was extracted (QIAamp® DNA Blood mini kit) from 3 mL of EDTA-anticoagulated 
blood.  G-to-A transition for C282Y and C-to-G substitution for H63D mutation of HFE gene were 
detected by AS PCR in an ABI Prism 7300 Sequence Detection system (Applied Biosystems).  
Frequencies of categorical variables were compared using the Fisher exact test or Chi Squared test 
where appropriate. Numerical variables were compared using Mann-Whitney U test. The Spearman 
rank correlation was used to assess the correlation between variables. Survival analysis was performed 
using methods of Kaplan and Meier and the log-rank test.
15
 All statistical tests were two-sided and P 
values <0.05 were considered significant. Due to a small number of patients, we analyzed all patients 
with mutated HFE gene (C282Y and H63D mutations) as one group in comparison to wild type 
patients. 
Results 
HFE mutations frequency  
HFE gene mutations were present in 11 out of 36 patients (31%). The C282Y mutation was present in 
three patients (8%), one patient was homozygous and the other two were heterozygote carriers. The 
H63D mutation was present in 9 patients (25%), all were heterozygous carriers. One patient was a 
compound heterozygote harboring both mutations. The HFE gene was mutated in 4 out of 13 patients 
with RA (31%), 4 out of 12 patients with RARS (34%), 3 out of 7 patients with RAEB (43%) and no 
mutations were present in the other 4 patients (Table 1).   
The reported prevalence of HFE gene mutations in the Croatian population is 32%, 6.5% and 26.5% 
for C282Y and H63D respectively.
16
 When compared, our patients’ mutated frequency did not differ 
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significantly (p=0.864, p=0.716 and p=0.851 for mutated HFE, C282Y and H63D respectively) (Table 
2). There were no significant differences in age at diagnosis, sex or need for blood transfusions 
between the mutated and wild type patients. 
Parameters of iron metabolism  
Increased values of transferrin bound iron, transferrin saturation and ferritin and decreased values of 
TIBC were observed in the mutated group of patients when compared to the wild type patients (Table 
3).  We observed a significant difference in the frequency of patients who developed iron overload 
(measured as ferritin over 1000 mcg/l) which was more prevalent in mutated group of patients (67% 
vs. 25%, p=0.044). We also observed a statistical significance for ferritin values (median 1113 mcg/l 
vs. 458 mcg/l, p=0.039) and TIBC values (median 39.4 mcmol/l vs. 50.7 mcmol/l, p=0.018).  The 
effect on ferritin concentrations was present and statistically significant in a subgroup of non-
transfused patients (p=0.017), but without any statistical significance between the mutated and the 
wild type patients in the subgroup of transfusion dependent patients. Ferritin levels correlated 
significantly with number of blood units received (Spearman Rho=0.52, p=0.04) and there was no 
significant difference in number of blood units received between mutated and wild type patients 
(median 54 vs. 57.5, p=0.562). 
Survival analysis by HFE status  
We observed a statistically significant effect of HFE gene mutations on the overall survival (OS) of 
MDS patients (p=0.004) (Figure 1 A). The overall survival at 36 months was 23% in the mutated 
group vs. 87% in wild type patients with a hazard ratio of 13.3. The median follow-up was 29 months.  
A statistical significant effect was also observed on leukemia free survival (LFS, p=0.003) (Figure 1 
B).  With the exclusion of patients with RAEB, significant changes in OS and LFS were still present (a 
total of 29 patients, p=0.003 and p=0.004 respectively). In addition, by excluding C282Y homozygous 
and C282Y/H63D compound heterozygous patients the study results were still significant (a total of 
34 heterozygous patients, p=0.032 and p=0.028 for OS and LFS respectively).  
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Discussion 
In our study, HFE gene mutations were as frequent among MDS patients as within the healthy 
population. In addition, we did not observe a significant increase in the frequency of HFE gene 
mutations in the RARS subgroup of patients, although such subgroup analysis is difficult to interpret 
based on the small study number. Noted differences among previous reports are at least in part 
mediated by a different geographical distribution of HFE gene mutations, but may also be affected by 
the mode of patient referral and the type of methodology used (exclusion of MDS in transformation 
patients, study design).  
HFE mutational status undoubtedly affects iron metabolism, especially with the high risk genotype 
that can lead to hereditary hemochromatosis (homozygosity for C282Y).
17, 18
 When excessive body 
iron saturates reusable ferritin storage, it is deposited in form of water-insoluble hemosiderin which 
can be an initiator of reactive oxygen species
19, 20
 and lead to adjacent tissue damage and malignant 
transformation. It is this mechanism that has been implicated in development of hepatocellular 
carcinoma and other malignancies in patients with hereditary hemochromatosis
21, 22
 and is also 
suspected to be a possible mechanism of defective hematopoiesis in some MDS patients.
7, 23
 Single 
heterozygosity for these mutations does not lead to overt iron accumulation as shown by the 
aforementioned population studies.
10-14
 As our results show (mainly heterozygote patients, one C282Y 
homozygote, one C282Y/H63D compound heterozygote), mutations in HFE gene have a profound 
effect on ferritin and TIBC values in myelodysplastic syndrome. The effect on ferritin is present in a 
subgroup of non-transfused patients, suggesting that the mutated HFE gene contributes to intrinsic 
characteristic of MDS to accumulate iron.  
One of the most intriguing observations made in this study, not previously reported, is the effect of the 
mutated HFE gene on the overall survival and leukemia free survival in patients with MDS.  These 
effects could be mediated by the aforementioned changes in iron metabolism. Both subclinical and 
manifest iron accumulation lead to an increase in the generation of free radicals and local tissue 
damage which in turn increases the chances of disease transformation to acute leukemia or death.  The 
effect of HFE mutations on the survival of our patients cannot be attributed to transfusion dependency 
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as there are no significant differences in the number of blood units received or frequency of 
transfusion dependent patients between the mutated and the wild type group. In addition, the effect of 
the mutated HFE gene on survival is still present when patients with RAEB (entity with high risk for 
worst outcome) are excluded.  The limitations of this study encompass the small number of subjects 
and the inability to obtain International Prognostic Scoring System (IPSS) score for all patients 
involved. The described findings are an interesting contribution into the pathogenesis of MDS and are 
worth further investigation in future studies, as these studies are necessary in determining whether or 
not HFE mutated MDS patients should be considered for the obligatory institution of potent iron 
chelation therapy.  
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Table 1   
HFE genotype by MDS subtype. Total number and number of heterozygous patients (unless specially 
noted) are provided; hom. - homozygote 
MDS subtype C282Y H63D Wild type 
RA (13) 1  3 10 
RARS (12) 0 4 8 
RAEB (7) 1 C282Y/H63D, 1 C282Y hom. 1 4 
Unclassified MDS and 5q- (4) 0 0 4 
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Table 2 
Frequency of HFE mutations 
 MDS patients Controls
16
 p value 
Both mutations 11/37 (30%) 64/200 (32%) 0.864 
C282Y 3/37 (8%) 13/200 (7%) 0.716 
H63D 9/37 (24%) 53/200 (27%) 0.851 
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Table 3 
Parameters of iron metabolism (median values) 
 HFE mutated patients 
HFE wild type 
patients 
p value 
Fe 25.95 mcmol/l 18.9 mcmol/l 0.583 
TIBC 39.5 mcmol/l 50.7 mcmol/l 0.018 
Transferrin saturation 66% 37% 0.29 
Ferritin 1113 mcg/l 458 mcg/l 0.039 
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Figure 1  
A) Overall survival curves for the HFE wild type and mutated patients (p=0.004);  
B) Leukemia free survival curves for the HFE wild type and mutated patients (p=0.003) 
 
